Filing Flows › Repligen (RGEN) › R&D spending
Repligen (RGEN) R&D spending by quarter
Repligen's R&D spending was $14.4M in Q3 2026 (third quarter 2026), +0.1% from Q2 2026. Over the last 4 quarters it ranged from $12.9M (Q1 2025) to $14.5M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $14.4M | +0.1% | — |
| Q2 2026 | $14.4M | -0.3% | — |
| Q1 2026 | $14.5M | +12% | +12% |
| Q1 2025 | $12.9M | — | — |
Q3 2026 at a glance
Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%, net loss $38.4M, operating cash flow $43.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Repligen's R&D spending?
Repligen's R&D spending was $14.4M in Q3 2026 (third quarter 2026), +0.1% from Q2 2026.
How has Repligen's R&D spending changed?
Over the last 4 quarters it ranged from $12.9M (Q1 2025) to $14.5M (Q1 2026).